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REVIEW
Strategies for precision modulation 
of gene expression by epigenome editing:  
an overview
Benjamin I. Laufer*  and Shiva M. Singh
Abstract 
Genome editing technology has evolved rather quickly and become accessible to most researchers. It has resulted in 
far reaching implications and a number of novel designer systems including epigenome editing. Epigenome editing 
utilizes a combination of nuclease-null genome editing systems and effector domains to modulate gene expression. 
In particular, Zinc Finger, Transcription-Activator-Like Effector, and CRISPR/Cas9 have emerged as modular systems 
that can be modified to allow for precision manipulation of epigenetic marks without altering underlying DNA 
sequence. This review contains a comprehensive catalog of effector domains that can be used with components of 
genome editing systems to achieve epigenome editing. Ultimately, the evidence-based design of epigenome editing 
offers a novel improvement to the limited attenuation strategies. There is much potential for editing and/or correcting 
gene expression in somatic cells toward a new era of functional genomics and personalized medicine.
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Background
The modulation of gene expression can be achieved by 
a variety of biotechnologies such as RNA interference, 
non-precision drugs, and artificial transcription factors 
(ATFs). Epigenome editing is an emerging field of syn-
thetic biology that falls under the category of ATF [1]. It 
is distinguished from other gene expression modulation 
technologies in that it can create precise and long-last-
ing epigenetic modification without the need to keep or 
maintain the system after the initial event [2].
The epigenome editing systems that are the focus of 
this review contain the DNA-binding element of genome 
editing systems. Thus, in order to gain a full appreciation 
for epigenome editing one must start with the fundamen-
tals of genome editing as the two share not only com-
ponents but also obstacles. Genome editing represents 
a revolution in genetic engineering as it allows for pre-
cision targeting and manipulation of genome. Genome 
editing systems rely on two components, a DNA-bind-
ing element, and nuclease, to modify the targeted DNA 
sequence. Genome editing can be used to study protein 
function by altering coding sequence or achieve tran-
scriptional control by altering the sequence of regula-
tory regions. Epigenome editing, on the other hand, uses 
the same DNA-binding principle but utilizes an effector 
domain, rather than a nuclease. The effector domain is a 
fragment of a desired regulatory protein and is used to 
create a desired epigenetic mark at a targeted locus with-
out altering the underlying sequence.
DNA‑binding genome editing systems
The concept of genome editing is not new. What is new 
is the refinement of methods that make it feasible for 
most laboratories to undertake the protocol success-
fully. Today, genome editing allows for precise manipula-
tion of DNA sequences and brings about desired genetic 
changes at will in  vitro and in  vivo [3–5]. The principle 
involves precise targeting of a specific DNA sequence 
in the genome to create a site-specific double-stranded 
break using a nuclease. A cell will then attempt to correct 
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this damage by homology-directed repair (HDR), which 
makes it possible to introduce desired donor sequence(s). 
Additionally, non-homologous end-joining (NHEJ) can 
be used to delete desired sequences. The methods avail-
able make use of Zinc Fingers (ZFs), Transcription-
Activator-Like Effectors (TALEs), and the Clustered 
Regulatory Interspaced Short Palindromic Repeats 
(CRISPR) sequences with CRISPR-Associated Protein 9 
(Cas9) detailed below.
ZFN
Zinc Finger Nuclease (ZFN) is the oldest genome edit-
ing technology [6–8]. It is based on two-modules. The 
first are Zinc Finger Proteins that recognize and bind to 
DNA sequences. Zinc finger proteins coordinate zinc 
ions using a backbone of conjugated Cysteine (Cys) and 
Histidine (His) residues to achieve their structure. They 
come in a number of folding groups the most widely used 
being the Cys2His2 group. This folding group represents 
the classical zinc finger and is widely used as a natural 
transcription factor in mammals. Cys2His2 ZFs also have 
a relatively conserved backbone. ZF specificity for DNA 
sequence comes from a part of the α helix, known as the 
recognition domain, which binds to the major groove of 
DNA. The specificity is determined by amino acids in 
the recognition domain. Variation in this region, either 
naturally occurring or synthetic, results in recognition 
of alternative nucleic acid sequences. Experimentally, a 
designer zinc finger is fused to a nuclease (FokI), which 
requires dimerization for double-stranded DNA cleav-
age. Here, the targeting specificity comes about from the 
recognition domain, with each ZF recognizing 3–4  bp 
per amino acid in the domain. Typically, ZFN systems 
use a combination of 3–6 ZFs fused to a FokI domain. 
The inverted dimer required for nuclease activity gives 
additional sequence specificity as there is a required 
space, known as the spacer. This design approach facil-
itates a target specificity of ~24  bp, which is enough to 
target most unique regions in most genomes (Fig.  1a). 
In terms of practicality, ZFNs are limited by the higher 
cost and effort of designing the custom proteins, inter-
actions between residues affecting targeting, and altered 
sequence recognition from the effects of additional 
genomic and chromatin content surrounding the target 
sites [9]. However, they have the advantage of being old-
est, most studied, and only genome editing system to be 
in clinical trials.
TALEN
TALENs represent a fusion of a Transcription-Activator-
Like Effector (TALE), which is a viral element evolved to 
target plant transcription and a designer nuclease [10–
12]. TALEs have a central repeat domain that confers 
its sequence specificity (Fig.  1b). This domain is 33–35 
amino acids long and has two highly variable sites at 
the 12th and 13th amino acids, which are known as the 
repeat variable di-residues (RVDs). Different combina-
tions at the RVDs allow for recognition of a single base. 
While both ZFN and TALEN systems theoretically allow 
for single-base targeted design, TALEs recognize single 
nucleotides as opposed to the triplet combinations of a 
ZFPs recognition sequence. Also, this system performs 
better than ZFNs since they are not as influenced by 
sequence and chromatin surrounding the target site [13–
17]. More importantly, TALEs and TALENs represent a 
significant improvement in specificity and protocol [18, 
19].
TALENs have been successfully used in mice for mito-
chondrial transfer, which allows for a 3-parent child. This 
is done in order to prevent an inherited disorder in the 
mitochondrial genome that would normally be transmit-
ted from the mother. It has recently been approved as a 
medical procedure in the UK and is currently under seri-
ous consideration in USA. Intriguingly, a mitoTALEN 
system was recently used in mice to overcome mitochon-
dria heteroplasmy by targeting and selectively destroying 
diseased mitochondria but still allowing for the transmis-
sion of wild-type mitochondria in mouse oocytes from 
the original mother [20].
CRISPR/Cas9
This system also consists of two components. First, the 
Cas9 protein is a nuclease. Second, the CRISPR/Cas9 sys-
tem consists of a synthetic guide RNA (sgRNA) [21]. The 
sgRNA is used for sequence specificity and has a 20  bp 
target recognition domain. However, the sgRNA contains 
more information than just targeting specificity and has a 
complex stem loop structure. The loading of the sgRNA 
is critical for activating the catalytic activity of Cas9 [22]. 
The binding and catalytic activity of the Cas9/sgRNA 
complex on target DNA is also dependent on the pres-
ence of an external sequence known as the Protospacer 
Adjacent Motif (PAM) [23]. Target DNA sequences 
complementary to the sgRNA are ignored by the Cas9/
sgRNA complex if PAM is not present upstream of the 
target DNA. This is because DNA strand separation and 
the RNA–DNA heteroduplex are initiated at the PAM 
site (Fig. 1c). While there are target sequence limitations 
created by the requirement of PAM before the target 
sequence, research into overcoming the initial limitations 
is showing that by using Cas9 orthologs with alternative 
PAM sequences [24–26] and distinct sgRNA recognition 
sequences [27] there may be no practical limit to the targ-
etable sites in the genome. Another practical advantage of 
CRISPR/Cas9 is the relative ease of creating short custom 
nucleotide (<100 bp) sequences compared to engineering 
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proteins to bind different sequences while also maintain-
ing activity and specificity. The CRISPR/Cas9 protocol 
[28–32] has undergone numerous improvements, allow-
ing it to become the most widely used genome editing 
system. The advantage of CRISPR/Cas9 over ZFNs and/
or TALENs is its scalability in that multiple sites within 
the mammalian genome can be modified simultaneously, 
providing a robust, high-throughput approach for gene 
editing in mammals. These advantages in this system are 
largely due to the fact that RNA, instead of designed pro-
tein, is used to specify the target.
The CRISPR system has been adapted to target double-
strand breaks and modify DNA sequence in the genomes 
of a number of organisms including humans [33], mice 
[34], and zebrafish [35]. In fact CRISPR/Cas9 has been 
adopted to work in species ranging from prokaryote to 
eukaryote, plant to animal, and vertebrate to invertebrate. 
Of particular interest is the fact that in its earliest stages 
of development CRISPR/Cas9 has been used to alter the 
mouse by using a knockin system [36, 37] and also ena-
bled reverse genetic studies in post-mitotic neurons of 
the adult brain [38]. CRISPR/Cas9 has also been used 
to generate one-cell embryos that go on to develop into 
edited monkeys [39]. Finally, it has been demonstrated 
to deplete synaptic proteins in rat hippocampal neuron 
cultures [40] and correct the mutation in the hemoglobin 
beta gene responsible for sickle cell anemia [41]. This was 
done in blood cells derived from induced pluripotent 
stem cells (iPSCs) of patients and with a higher efficiency 
than possible using ZFNs and TALENs [41, 42].
The CRISPR/Cas9 system can also be used to create 
gene drives [43]. Gene drives are a synthetic biological 
system in which a transgene can aggressively propagate 
independently of natural selection. It can quickly take 
over a population in a few generations with only just a 
few founders. This is because the mutation edited into 
Fig. 1 (Epi)Genome editing systems. a Zinc Finger Nuclease (ZFN), b Transcription-Activator-Like Effector Nuclease (TALEN), c CRISPR/Cas9, d Zinc 
Finger (ZF) with a DNA methyltransferase effector domain, e Transcription-Activator-Like Effector (TALE) with a histone methyltransferase, and f 
Catalytically deactivated Cas9 (dCas9) and sgRNA from with a histone acetyltransferase. Components are not to scale as critical features are exagger-
ated and some non-variable features are removed
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a founder will overwrite the content of the wild-type 
parent in their offspring, thus it overcomes the dip-
loid genome and makes an inherited heterozygote and 
homozygote [44].
Genome editing the epigenome
Genome editing systems can also be used to edit the 
epigenome in a fashion that is distinct from epigenome 
editing, as it involves altering sequence critical to the epi-
genome. CRISPR/Cas9 has been utilized to study chro-
matin architecture and make targeted and unprecedented 
alterations to the repeat rich regulatory elements. It cre-
ated deletions, inversions, and duplications that enabled 
the study of the clustered protocadherins [45], a complex 
locus that generates individual neuronal identity and 
is involved in neurodevelopmental disorders [46]. The 
approach has lead to the discovery of regulatory elements 
from the protocadherin α cluster that are also involved 
in the regulation of the γ cluster. Finally, CRISPR/Cas9 
has been used to remove CTCF binding sites in the Hox 
gene clusters during embryonic stem cell differentiation 
in cervical motor neurons and disrupt the topological 
chromatin boundaries, turning repressed chromatin into 
active chromatin by preventing CTCFs targeted func-
tion as a genomic insulator [47]. Also, TALENs have been 
used to study long-range chromatin interactions by alter-
ing the sequence of inter- and intra-chromosomal con-
tact points [48].
Furthermore, the cross-species capability of CRISPR/
Cas9 has lead to profound insight in mammalian sys-
tems that were previously inaccessible at the level of 
basic research, particularly in monkeys [49] and humans. 
CRISPR/Cas9 has already been used to investigate DNA 
methylation machinery. Two genome editing approaches 
were developed in an in  vivo mouse model, one had a 
single gene approach to target the reader MeCP2 that 
allowed for visualization and cell sorting and the other 
had a multi-gene approach to target the DNA methyl-
transferases (DNMTs) Dnmt1, Dnmt3a, and Dnmt3b 
[38]. More recently, the CRISPR/Cas9 system was used 
for experimentation in human embryonic stem cells to 
create precise knockout deletions in the DNMTs [50]. 
By creating catalytically inactivating mutations using 
both multiplex and singleplex approaches the targets of 
DNMT1, DNMT3A, and DNMT3B were mapped with 
single-base pair resolution via whole-genome sodium 
bisulfite sequencing. This study was done in reference 
to a previous mouse model study of embryonic stem 
cells [51]. In both humans and mice, ESCs are viable 
without DNMT3A or DNMT3B, but interestingly only 
human cells undergo rapid cell death from the removal of 
DNMT1. This occurred even with an inducible system to 
control the temporal disruption, where cell death occurs 
immediately upon inducing repression of the system 
masking the homozygous mutation. Thus, the CRISPR/
Cas9 technology was able to illustrate a fundamental dif-
ference between humans and mice.
Epigenome editing
Besides editing genome sequence, genome editing sys-
tems have been used in altering the transcription of spe-
cific gene(s) without altering the underlying sequence. 
This modification for transcriptional alterations involves 
exclusion or inactivation of nuclease activity followed 
by use of the targeting system fused to a modular effec-
tor domain and is known as epigenome editing. A list of 
effectors and their effects on gene expression (increase or 
decrease) is summarized in Table  1. However, it should 
be noted that the effect of epigenetic marks is context 
dependent and thus the context of this table is the aver-
age consequence of depositing these marks in a promoter 
or enhancer. These systems have been used to target inte-
grated/synthetic as well as endogenous loci, a distinction 
that is reviewed by de Groote et al. [1].
The function of ATF was the primary purpose for 
DNA sequence specificity of designer ZFs and TALEs 
with the goal of precise transcriptional activation, 
also known as transactivation. Transactivation effec-
tor domains are based on viral elements. The origi-
nal VP16 domain [52] comes from Herpes Simplex 
Viral Protein 16 and consists of amino acids 437–447 
[DALDDFDLDML]. VP16 was later engineered into 
VP64 domain [53], which is a fusion containing four 
tandem copies of VP16 connected by glycine-serine 
linkers [DALDDFDLDML]-GS-[DALDDFDLDML]-GS-
[DALDDFDLDML]-GS-[DALDDFDLDML]. It is the 
most widely used transactivation domain. Interestingly, 
one effect of using the VP64 transactivation domain is 
that it recruits p300, which causes activating H3K27Ac 
to increase at the targeted locus over time and repre-
sents an example of transcription driving transcription 
[54]. Transcriptional repression, on the other hand, uti-
lizes repression domains [55, 56] and is typically achieved 
by variants of a 45-aa segment from Krüppel-associated 
boxes (KRAB) [55] or repressive epigenomic modifica-
tions [57, 58]. The KRAB repressor domain appears to be 
the most potent natural repressor in the genome and used 
by half of zinc fingers, which make up half of the genome’s 
transcription factors. Interestingly, the KRAB repressor 
domain recruits histone modifying domains and results in 
a decrease of activating H3K4me3 and increase of repres-
sive H3K9me3 and H3K27me2 but does not alter DNA 
methylation [59]. However, these modifications may not 
reflect the immediate effect of transcriptional repression 
and could be a later consequence [60]. A bacterial DNA 
methyltransferase (M.SssI) is also capable of repression 
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Table 1 A comprehensive selection of effector domains for epigenome editing systems
Effect Domain Consequence Reference(s)
Activation VP64
VP16
p65
SAM
VPR
Activates transcription by recruiting a transcription complex and can 
then recruit histone acetylation as a consequence of the induced 
transcription. Can recruit p300 to deposit H3K27ac
Seipel et al. [52]
Beerli et al. [53]
Konermann et al. [57, 84]
Gilbert et al. [81, 87]
Mali et al. [83]
Perez-Pinera et al. [30]
Kearns et al. [85]
Hu et al. [95]
Tanenbaum et al. [96]
Gao et al. [54]
Chakraborty et al. [90]
Heller et al. [125]
Zalatan et al. [88]
Nihongaki et al. [102]
Polstein and Gersbach [103]
Chavez et al. [97]
Repression KRAB
SID
Tbx3-RD
Represses transcription by preventing transcription complex formation. 
May also recruit other repressive modifications
Margolin et al. [55]
Ayer et al. [56]
Cong et al. [17]
Gilbert et al. [81, 87]
Chen et al. [105]
Kearns et al. [85]
Hu et al. [95]
Ma et al. [59]
Gao et al. [54]
Zalatan et al. [88]
Telese et al. [89]
DNA methylation DNMT3A DNMT3B
M.EcoHK31I
M.HhaI
M.SssI
DNMT3A-3L
Represses transcription Li et al. [63]
Meister et al. [64]
Chaikind et al. [66, 69]
Rivenbark et al. [65]
Siddique et al. [67]
Nunna et al. [68]
Stolzenburg et al. [70]
Kungulovski et al. [71]
Bernstein et al. [76]
DNA demethylation TDG
TET1
TET2
Activates transcription Gregory et al. [72]
Maeder et al. [73]
Chen et al. [78]
H3K9me G9a (EHMT)
Suvar
KYP
GLP
Represses transcription Snowden et al. [61]
Falahi et al. [62]
Konermann et al. [57]
Heller et al. [125]
Kungulovski et al. [71]
Cho et al. [74]
H3K9 demethylation JMJD2B Activates transcription Hu et al. [95]
H3K9 deacetylation Sin3a Represses transcription Konermann et al. [57]
H3K4me2 demethylation LSD1 Also leads to H3K27ac removal; both repress transcription.  
Ideal for enhancers
Mendenhall et al. [75]
Kearns et al. [58]
H3K27me3 NUE Represses transcription Konermann et al. [57]
H3K27 demethylation JMJD3 Activates transcription Hu et al. [95]
H3K27ac p300 Activates transcription. Ideal for enhancers Hu et al. [95]
Hilton et al. [91]
H4K8 deacetylation HDAC8
RPD3
Sir2a
Represses transcription Konermann et al. [57]
H4K20me3 tgSET8 Represses transcription Konermann et al. [57]
Affinity enrichment PrA
FLAG
Locus-specific chromatin enrichment for protein analysis Byrum et al. [109, 113]
Fujita et al. [110, 111]
Waldrip et al. [112]
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and recruiting a heterochromatin protein, H3K9me3, and 
H3K27me2 [59]. The following are examples of how some 
of these effector domains have been used with DNA-
binding platforms to modulate gene expression.
Zinc Fingers
The ZF system has been extensively used as an artificial 
transcription factor (Fig.  1d). It was first used to estab-
lish epigenome editing in 2002 when an engineered ZF 
fused to a histone methyltransferase was able to show 
that H3K9 methylation is causative in gene repression 
[61]. Since then ZFs have been designed with histone 
methyltransferases to repress oncogenes [62]. ZFs have 
also been utilized with DNA methylation machinery. In 
these cases, the DNA methyltransferases (DNMTs) were 
fused to designer ZFs to cause targeted DNA methyla-
tion and repress related gene expression [63–70]. Such 
designs have varied from engineered bacterial meth-
yltransferases to select domains of the mammalian 
DNMT family. Recently, a ZF fused to DNMT3A or the 
H3K9 methylation writer GLP were delivered by adeno-
viral delivery system to control the regulation of a can-
cer gene by targeting its promoter [71]. While DNA 
methylation repressed longer than H3K9 methylation, 
the effect was not long-lasting and the authors specu-
late that multivalent epigenetic modifications must be 
designed for long-term effects when epigenome editing 
and to accommodate for large-scale chromatin domains. 
One promising design of effector domain involves a 
fusion of the catalytic domain of the de novo methyl-
transferase DNMT3A and C-terminal domain of (the 
catalytically inactive) DNMT3L, which naturally stimu-
lates DNMT3A’s activity [67]. Alternatively, ZFs can be 
used to enhance gene expression by being fused with the 
DNA demethylase thymidine DNA glycosylase (TDG) 
[72]. However, epigenetic editing by ZFs is prone to the 
same problems as genome editing, genome wide off-tar-
get effects caused by the nature of ZF recognition being 
altered by additional (epi)genomic context [60].
TALEs
Taking the modular approach of ZFs, TALEs have been 
modified to induce transcriptional activation [73] and 
repression [74] (Fig.  1e). TALE epigenome editing sys-
tems have been used to target and modify chroma-
tin at enhancers [75] and regulate gene expression via 
DNA methylation [76]. Furthermore, using a combina-
tion of epigenome editing systems and optogenetics 
for light induction, it was shown that gene expression, 
histone acetylation (H3K9ac) and histone methylation 
(H3K27me3) in the mouse brain can be targeted and 
modulated in a reversible fashion [57] at will. TALEs have 
also been efficiently fused to the TET family of active 
DNA demethylases and drive gene expression in targeted 
sequences by actively removing DNA methylation [77, 
78]. The fusion of the DNMT3A and DNMT3L was repli-
cated in TALEs [76].
dCas9
The CRISPR/Cas9 system has also been used to alter tran-
scription [79–88]. This has been achieved by targeting 
with sgRNAs and a catalytically inactivated Cas9 (dCas9), 
which creates a RNA-based targeting system that can be 
fused to effector domains. Therefore, dCas9 based epige-
netic editing gains the target specificity of CRISPR/Cas9 
without causing a double-stranded break and while car-
rying out the function of the effector domain at the target 
site (Fig.  1f ). A dCas9 system fused to the KRAB tran-
scription repressing domain has been used to confirm the 
function of LRP8-Reelin-regulated neuronal enhancers 
in cortical neurons and lead to the discovery of a novel 
synapse-to-nucleus pathway related to glutamatergic 
signaling [89]. However, in the context of transcriptional 
control the dCas9 system often achieves low effective-
ness, which can be improved by the tiling of multiple 
sgRNAs. Yet another approach to transcription activation 
via dCas9 has been to fuse two activation domains per 
dCas9. This system was used to reprogram the cell line-
age of stem cells and drive subsequent phenotypes [90]. 
Also, the histone acetyltransferase p300 can be used as an 
effector domain to achieve H3K27 acetylation and induce 
gene expression by targeting the mammalian β-globin 
locus control region, which is something that could not 
be achieved by a VP64 domain [91].
Since each system has its own strengths and weak-
nesses when it comes to off-target and on-target effects, 
price, cellular toxicity, and ease of use, a standardized 
comparison system is needed [92, 93]. In practice, each 
system may show a unique potential when used on 
their own or coupled together [94]. This has recently 
been exemplified in the case of transcriptional activa-
tion of pluripotency factors in humans and mice by both 
Table 1 continued
Effect Domain Consequence Reference(s)
Cell imaging GFP
Cherry
BFP
Sub-nuclear visualization Chen et al. [46]
Anton et al. [106]
Ma et al. [108]
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CRISPR- and TALE-based editing systems [95]. When 
comparing the ability to drive gene expression by target-
ing enhancers, it was found that TALEs could outper-
form CRISPR/Cas9 and the authors recommended an 
approach combining both systems for highly efficient 
transcriptional regulation [54]. However, this comparison 
used initial and less effective CRISPR activators and not 
the most enhanced genetically engineered improvements 
[84, 87] that are described below.
Engineered improvements
Several laboratories have begun to utilize the geneti-
cally engineered Cas9 proteins and sgRNAs (Fig.  2). 
One alterative involves a versatile scaffolding platform 
to attach multiple VP64 domains to dCas9 [96]  and a 
different approach uses the tripartite activator VP64-
p65-Rta (VPR) [97]. Another variation is the use of sec-
ond-generation sgRNAs (sgRNA 2.0) for multi-effector 
programming [88], where scRNAs (extended sgRNAs) 
have effector domain recruitment sites added into their 
sequence after the targeting site. This approach further 
creates modularity in that there are layers of variation 
created in Cas9 orthologs having different sgRNA recog-
nition sites. Additional layers are then created by the fact 
that each sgRNA can be programmed to have two recog-
nizable loops that can be bound in homogenous or het-
erogeneous configurations by a unique binding protein 
being fused to unique effector domains [88]. One exam-
ple of this system is the Synergistic Activation Media-
tor (SAM), which is a potent transcription activation 
system [84]. In SAM, the exposed and engineered RNA 
loops from the Cas9–sgRNA–DNA complex are used as 
anchoring points for the RNA-binding protein (MS2) that 
is also fused to a p65-HSF1 fusion effector domain. This 
allows for a synergistic combination in activating gene 
expression at levels much higher than a single effector 
domain. Another approach involves further enhancing 
the sgRNA to create a system known as CRISPR-Display 
[98]. CRISPR-Display allows for functional RNA domains 
(~4.8 kb) to be inserted into the sgRNA loops at multi-
ple positions, including the same loop as sgRNA 2.0 as 
well as 5′ and 3′ positions. This approach uses functional 
motifs like the protein-binding cassettes of earlier sgRNA 
2.0 approaches but also enables long non-coding RNA to 
be inserted into the dCas9/sgRNA complex. Ultimately, 
the CRISPR-Display system enables precision ectopic 
targeting of RNA and ribonucleoprotein to loci of inter-
est in order to fully characterize the functionality of the 
RNA.
Combinatorial biotechnology
(Epi)genome editing systems allow not only for fusing a 
genome editing system to an effector but they can also 
add additional genetic changes and facilitating method-
ologies. For example, Konermann et  al. [57] used tran-
scriptional control or histone modifying (acetylation 
and methylation) effector domains (Table  1) along with 
a light inducible (optogenetic) element. The optogenetic 
induction system involves light-sensitive cryptochrome 
2 (CRY2) and CIB1, its binding partner [99]. These two 
proteins only heterodimerize upon exposure to blue 
light, a process that is rapid and reversible, and can be 
applied to study neurons in mammalian brains [100, 101]. 
They can then be separately fused to an epigenome edit-
ing system, with one attached to the targeting system 
and the other to the effector. This can be utilized in epi-
genome editing by allowing for the editing to be induced 
when and where it is desired in a rapid and reversible 
manner. The optogenetic approach has also been com-
bined with CRISPR/Cas9 transactivation systems [102, 
103]. Alternate inducible transactivation systems use 
steroids that has been created using TALEs [104]. Finally, 
cell imaging can also be achieved using an EGFP effector 
domain [105] that can visualize pericentric, centric, and 
telomeric repeats [106]. This allows for the visualization 
of repetitive sequences using a single sgRNA or an array 
of sgRNAs for non-repetitive sequences to enable visuali-
zation and tracking through cellular processes. This tech-
nique was demonstrated by imaging telomere dynamics 
and the dynamic sub-nuclear localization of a single gene 
through mitosis. Another visualization system has been 
developed that allows for multicolor analysis. It was ini-
tially successful in TALEs [107] and was recently adopted 
for dCas9 orthologs with three spectral systems [108]. 
The spectral systems were used to target telomeres, sev-
eral target loci, and also determine the intranuclear dis-
tance between loci on different chromosomes, which 
allowed for the assessment of DNA compaction in live 
cells.
Furthermore, epigenome editing systems have been 
used for enrichment and purification of proteins inter-
acting with target loci. They have the potential to allow 
for an examination of all the proteins and histone PTMs 
associated with a single genomic locus, the epiproteome 
[109]. These techniques couple chromatin immunopre-
cipitation and the target specificity of genome editing 
systems (without the catalytic activity) by using an effec-
tor domain to allow for enrichment that can then be 
coupled to analysis by mass spectrometry. One variant 
of this approach is known as engineered DNA-binding 
molecule-mediated chromatin immunoprecipitation 
(enChIP). It has been developed using TALEs [110] and 
CRISPR/Cas9 [111] to study telomeres. Another vari-
ant involving the CRISPR/Cas9 system has also been 
developed and termed Chromatin Affinity Purification 
with Mass Spectrometry (CRISPR-ChAP-MS) [112]. 
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This approach was able to reveal the changes during 
the activation of transcription although it had difficulty 
with repressive contexts, including when using TALEs 
[113]. The developments identified above represent some 
selected issues that will be further enabled using epig-
enome editing technology. More importantly, we antici-
pate additional future modifications and applications of 
this system to provide insights into other biological prob-
lems that have remained difficult to investigate.
Future challenges
A flurry of publications in recent years have established 
that (epi)genome editing may hold the key to the next 
generation of genomic revolution; the alteration of gene 
sequences as well as its expression in designated tissues at 
will. To date, most of this research has focused on under-
standing biological complexities including correction of 
gene defects that may be associated with diseases. It is also 
apparent that genome editing systems have met a number 
Fig. 2 Designer epigenome editing systems based on dCas9. VPR refers to the effector domain, which is a tripartite design. sgRNA 2.0 refers to a 
scaffolding system that allows for modular effectors to be added to the sgRNAs that have been modified to contain protein-binding sites for RNA 
recognizing proteins. SAM refers to a synergistic activator that contains an effector domain fused to the dCas9 protein as well as the sgRNA 2.0 
design to add additional designer activators. Components are not to scale as critical features are exaggerated and some non-variable features are 
removed
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of challenges in providing the needed proof of principle 
for epigenome editing systems. These include off-target 
effects, editing efficiency, delivery [114–116], and cyto-
toxicity [117]. In particular given the complexity of the 
genome sequence and organization, it may not be easy to 
avoid off-target effects in most if not all cases, particularly 
in the highly open and dynamic chromatin of embryos 
that is not well characterized. These limitations mean that 
only some of the cells in question will have the desired out-
come. This level of correction and expected somatic mosa-
icism may be sufficient in some but not all cases.
It is apparent that most research on genomic correction 
in humans will involve ex vivo methods [118]. The ex vivo 
approach involves harvesting appropriate cells from the 
patient, correcting them in culture, and then returning 
the corrected cells via autologous transformation. The 
in  vivo approach involves directly transforming somatic 
cells in the patient. On the other hand, ZFs can cross cell 
membranes and induce genome editing in human cells 
[119, 120]. Furthermore, incorporating tandem nuclear 
localization signal repeats into the ZFN protein backbone 
may improve cell permeability to ~13-fold and allow for 
genome modification success rates of 26  % in CD4+ T 
cells and 17 % in CD34+ hematopoietic progenitor cells 
[121]. TALENs can also be modified for enhanced cell 
penetrating abilities by conjugating with peptides that 
allow for optimized protein machinery delivery. It may 
allow for effective parallel viral transfection [122]. Cas9 
and sgRNAs have also been utilized for effective genome 
editing that does not require transformation of the edit-
ing system into host by using common cationic lipid 
nucleic acid transfection reagents to deliver the system 
[123] or by using electroporation [124]. As it stands, 
there are still key obstacles to overcome with epigenome 
editing but given the exponential rate of advancement 
most technological limitations will shortly be overcome.
Conclusion
It is apparent from the examples listed above that future 
application of epigenetic correction using the current 
and evolving technologies is only limited by imagination. 
Besides monogenic diseases, epigenome editing may 
apply in cases of complex traits, such as the long-term 
effects on neuroplasticity from stress and drug exposure. 
A recent example showed that a locus-specific epigenetic 
remodeling may control cocaine addiction- and depres-
sion-related behaviors [125]. This study used ZFs and 
TALEs to target histone methylation (H3K9me2 via G9a) 
or acetylation (correlated with transcriptional activator; 
p65) at transcription factor binding sites (SRF and CREB) 
of the Fosb promoter in the nucleus accumbens, a brain 
region involved in reward and addiction.
There is every reason to argue that cell-type-specific 
epigenome editing systems should be used to modify cells 
in vivo and/or in vitro to further basic science as well as 
correct a variety of diseases. Ultimately, epigenome edit-
ing represents a much-needed tool for the advancement 
of functional genomics and personalized medicine. Yet, 
until the trans-generational and population level conse-
quences are fully understood and debated it must remain 
limited to somatic cells and not cross to  the human 
germ-line.
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